50 results
8-K
EX-99.1
PTPI
Petros Pharmaceuticals Inc
13 Jul 23
Petros Pharmaceuticals Announces Capital Raise of $15 million
4:41pm
investment and support by our largest shareholders highlight their commitment to our strategy, sharing our excitement and passion … execution of an OTC strategy.
“According to Market.us, it is estimated that the total ED market will reach $6.1 billion by 2032 with an average CAGR
8-K
EX-99.1
PTPI
Petros Pharmaceuticals Inc
15 Nov 22
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
8:30am
with marketing activities and sales efforts around the product, our strategy will be primarily focused on the achievement of this goal.
“The model … to be an important part of our overall strategy, our primary objective will be achieving OTC access for this drug, significantly expanding the market
8-K
PTPI
Petros Pharmaceuticals Inc
2 Dec 20
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
9:14am
Operations and Business Strategy & General Manager, Established Brands Portfolio for Endo International plc, where he worked closely with the President … of the Branded Pharmaceuticals business to set, measure and refine the strategy for the business unit while leading a team of 20 people who provided
8-K
EX-99.1
PTPI
Petros Pharmaceuticals Inc
15 Aug 22
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022
9:16am
and strategy changes, and depreciation and amortization and to evaluate the Company’s ability to service debt. In addition, Adjusted EBITDA is a financial … ,” “continue,” “potential,” “opportunity,” “forecast,” “should,” “target,” “strategy” and similar expressions, whether in the negative or affirmative
8-K
EX-99.1
PTPI
Petros Pharmaceuticals Inc
30 Nov 22
Petros Pharmaceuticals Announces Reverse Stock Split
4:05pm
,” “continue,” “potential,” “opportunity,” “forecast,” “should,” “target,” “strategy” and similar expressions, whether in the negative or affirmative … ’ ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros’ ability to comply
8-K
EX-99.1
alrrb6l ctt6ui8frz
4 Apr 22
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights
4:15pm
8-K
EX-99.1
ijybyth
16 Nov 21
Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
b9iajulm84cnrc54ot5c
28 Jul 22
Other Events
11:26am
8-K
EX-99.1
yzplh4wu097 pxgf1t
26 Apr 22
Other Events
4:30pm
8-K
EX-99.1
fpycu7
15 Oct 21
Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering
5:03pm
8-K
EX-99.1
kxf4sqds6qejiiwn
27 Dec 21
Petros Pharmaceuticals Announces $7.5 Million Offering
5:02pm
8-K
EX-99.1
0el7u jnszh48iqn2n
1 Dec 21
Petros Pharmaceuticals Announces $10 Million Offering
5:12pm
8-K
EX-99.1
2haj3e7fmie
2 Dec 20
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
9:14am
10-K
lfjww86h v8jx
31 Mar 21
Annual report
4:30pm
424B5
4rv0 z6kxm51
1 Dec 21
Prospectus supplement for primary offering
5:10pm
424B5
e25p0 umf1qy
23 Dec 21
Prospectus supplement for primary offering
5:01pm
424B5
e5y13wi9 lewjvd
15 Oct 21
Prospectus supplement for primary offering
5:01pm